Updates on Epstein-Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV.


Journal

Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208

Informations de publication

Date de publication:
20 Dec 2022
Historique:
received: 20 11 2022
revised: 19 12 2022
accepted: 19 12 2022
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 25 1 2023
Statut: epublish

Résumé

Nasopharyngeal carcinoma (NPC) is an uncommon type of malignancy/cancer worldwide. However, NPC is an endemic disease in southeast Asia and southern China and the reasons behind the underlying for such changes are unclear. Even though the Epstein-Barr infection (EBV) has been suggested as an important reason for undistinguishable NPC, the EBV itself is not adequate to source this type of cancer. The risk factors, for example, genetic susceptibility, and environmental factors might be associated with EBV to undertake a part in the NPC carcinogenesis. Normal healthy people have a memory B cell pool where the EBV persists, and any disturbance of this connection leads to virus-associated B cell malignancies. Less is known about the relationship between EBV and epithelial cell tumors, especially the EBV-associated nasopharyngeal carcinoma (EBVaNPC) and EBV-associated gastric carcinoma (EBVaGC). Currently, it is believed that premalignant genetic changes in epithelial cells contribute to the aberrant establishment of viral latency in these tumors. The early and late phases of NPC patients' survival rates vary significantly. The presence of EBV in all tumor cells presents prospects for the development of innovative therapeutic and diagnostic techniques, despite the fact that the virus's exact involvement in the carcinogenic process is presently not very well known. EBV research continues to shed light on the carcinogenic process, which is important for a more comprehensive knowledge of tumor etiology and the development of targeted cancer therapeutics. In order to screen for NPC, EBV-related biomarkers have been widely used in a few high-incidence locations because of their close associations with the risks of NPC. The current review highlights the scientific importance of EBV and its possible association with NPC.

Identifiants

pubmed: 36676626
pii: medicina59010002
doi: 10.3390/medicina59010002
pmc: PMC9863520
pii:
doi:

Substances chimiques

RNA 63231-63-0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Higher Education
ID : FRGS/1/2020/SKK0/USM/02/22

Références

Gut Liver. 2011 Jun;5(2):143-8
pubmed: 21814592
PLoS Pathog. 2011 May;7(5):e1001338
pubmed: 21573183
Semin Cancer Biol. 2012 Apr;22(2):154-61
pubmed: 22206863
World J Gastroenterol. 2008 Jul 21;14(27):4347-51
pubmed: 18666324
Oral Oncol. 2022 Nov;134:106140
pubmed: 36183501
J Immunother. 2010 Nov-Dec;33(9):983-90
pubmed: 20948438
Diagnostics (Basel). 2021 Sep 25;11(10):
pubmed: 34679459
Lancet Glob Health. 2016 Sep;4(9):e609-16
pubmed: 27470177
Cell Death Differ. 2022 Aug;29(8):1513-1527
pubmed: 35105963
BMC Public Health. 2008 Dec 05;8:400
pubmed: 19055849
J Clin Pathol. 2004 May;57(5):487-91
pubmed: 15113855
Oral Oncol. 2022 Dec;135:106083
pubmed: 36332445
Cancer Res. 2012 Mar 1;72(5):1116-25
pubmed: 22282657
Cell Biol Toxicol. 2022 Jul 18;:
pubmed: 35844005
Eur J Cancer. 2021 Aug;153:109-122
pubmed: 34153713
Pathogens. 2012 Nov 08;1(2):156-74
pubmed: 25436768
Front Biosci. 2006 Sep 01;11:2672-713
pubmed: 16720343
Cancer Lett. 2014 Apr 10;345(2):174-81
pubmed: 23941825
Int J Mol Sci. 2020 Apr 15;21(8):
pubmed: 32326466
J Gen Virol. 2009 Feb;90(Pt 2):307-316
pubmed: 19141439
J Virol. 2005 Feb;79(4):2375-82
pubmed: 15681438
J Clin Invest. 2015 Sep;125(9):3365-76
pubmed: 26325033
Environ Pollut. 2022 Jul 1;304:119184
pubmed: 35341821
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1035-1047
pubmed: 33849968
Immunology. 2017 Oct;152(2):207-217
pubmed: 28695629
Mol Ther. 2003 Dec;8(6):964-73
pubmed: 14664799
Cancer Cell Int. 2021 Mar 10;21(1):164
pubmed: 33691680
Front Immunol. 2020 Jul 08;11:1444
pubmed: 32733479
Cancer Res. 2008 Feb 15;68(4):1030-6
pubmed: 18281477
Int J Mol Sci. 2022 Oct 03;23(19):
pubmed: 36233023
J Gastroenterol Hepatol. 2009 Mar;24(3):354-65
pubmed: 19335785
Clin Cancer Res. 2004 Mar 1;10(5):1698-705
pubmed: 15014022
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Postgrad Med J. 2008 Jul;84(993):372-7
pubmed: 18716017
Int J Cancer. 2006 Apr 1;118(7):1736-42
pubmed: 16217758
Cancer Causes Control. 2022 Jul;33(7):1013-1018
pubmed: 35441278
J Pathog. 2017;2017:7349268
pubmed: 29464124
Semin Cancer Biol. 2012 Apr;22(2):144-53
pubmed: 22249143
Nat Rev Clin Oncol. 2012 Sep;9(9):510-9
pubmed: 22801669
J Pathol. 2015 Jan;235(2):323-33
pubmed: 25251730
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14269-74
pubmed: 14603034
Semin Cancer Biol. 2012 Apr;22(2):79-86
pubmed: 22245473
Oncoimmunology. 2017 Jan 4;6(2):e1273311
pubmed: 28344888
J Gen Virol. 2003 Nov;84(Pt 11):2987-2992
pubmed: 14573803
Biochim Biophys Acta Mol Basis Dis. 2023 Feb;1869(2):166598
pubmed: 36372158
J Cancer Res Clin Oncol. 2022 Jul 25;:
pubmed: 35876949
Front Immunol. 2017 Sep 12;8:1132
pubmed: 28955343
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
Semin Cancer Biol. 2012 Apr;22(2):87-95
pubmed: 22154888
Cell Death Dis. 2022 Jul 30;13(7):664
pubmed: 35907914
Cancer Immunol Immunother. 2022 Jun;71(6):1531-1543
pubmed: 34661709
Clin Cancer Res. 2022 Dec 1;28(23):5221-5230
pubmed: 36165913
Expert Rev Mol Med. 2015 Aug 18;17:e15
pubmed: 26282825
Nat Rev Clin Oncol. 2021 Nov;18(11):679-695
pubmed: 34194007
Chin J Cancer. 2014 Dec;33(12):581-90
pubmed: 25418193
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6467-E6475
pubmed: 27698133
PLoS Pathog. 2021 Aug 18;17(8):e1009873
pubmed: 34407150
J Virol. 2011 Jul;85(14):7333-42
pubmed: 21543473
Pathogens. 2021 Aug 31;10(9):
pubmed: 34578147
J Infect Dis. 2006 Jan 15;193(2):287-97
pubmed: 16362894
Oral Oncol. 2022 Oct;133:106031
pubmed: 35908365
J Med Virol. 2023 Jan;95(1):e28387
pubmed: 36478267
Ann Oncol. 2019 Oct 1;30(10):1630-1637
pubmed: 31373615
Mol Cancer. 2022 Jul 28;21(1):154
pubmed: 35902864
Oral Oncol. 2022 Aug;131:105972
pubmed: 35728415
J Cancer Prev. 2017 Jun;22(2):62-73
pubmed: 28698859
Nat Rev Cancer. 2004 Oct;4(10):757-68
pubmed: 15510157
Head Neck Pathol. 2007 Sep;1(1):81-6
pubmed: 20614287
J Cancer Res Clin Oncol. 2015 Oct;141(10):1845-57
pubmed: 25920375
Oxid Med Cell Longev. 2022 Oct 3;2022:4479905
pubmed: 36225172
Clin Cancer Res. 2007 Sep 1;13(17):4993-5000
pubmed: 17785549
PLoS Pathog. 2011 Jul;7(7):e1002180
pubmed: 21829357
J Virol. 2011 Nov;85(21):11291-9
pubmed: 21880770
Clin Cancer Res. 2011 May 1;17(9):2885-92
pubmed: 21478335
Head Neck. 2008 Jul;30(7):946-63
pubmed: 18446839
J Clin Oncol. 2014 Mar 10;32(8):798-808
pubmed: 24344220
PLoS Pathog. 2012;8(5):e1002704
pubmed: 22615564
Signal Transduct Target Ther. 2021 Sep 4;6(1):333
pubmed: 34482361
J Virol. 2012 Jun;86(11):6146-58
pubmed: 22491455
J Exp Clin Cancer Res. 2022 Aug 20;41(1):254
pubmed: 35986369
Clin Transl Immunology. 2015 Jan 23;4(1):e32
pubmed: 25671130
Chin Med J (Engl). 2019 Mar 20;132(6):749-752
pubmed: 30855360
J Virol. 2004 May;78(10):5194-204
pubmed: 15113901
J Virol. 2014 Sep;88(18):10662-72
pubmed: 24991008
BMC Cancer. 2022 Aug 11;22(1):880
pubmed: 35953777
Semin Cancer Biol. 2020 Apr;61:84-100
pubmed: 31521748
Front Immunol. 2020 Feb 18;11:211
pubmed: 32133002
EBioMedicine. 2022 Oct;84:104267
pubmed: 36116213
Exp Ther Med. 2018 Apr;15(4):3687-3692
pubmed: 29556258
Cell Death Differ. 2012 Jan;19(1):5-12
pubmed: 22075986
Front Immunol. 2018 Mar 19;9:556
pubmed: 29616044
Biochem Pharmacol. 2021 Oct;192:114742
pubmed: 34428442
Clin Cancer Res. 2014 Oct 1;20(19):5009-22
pubmed: 25124688
Nat Genet. 2014 Jun;46(6):573-82
pubmed: 24816253
Int J Cancer. 2011 Aug 1;129(3):724-32
pubmed: 20878958
Ann Oncol. 2021 Apr;32(4):452-465
pubmed: 33358989
Sci Rep. 2020 Feb 12;10(1):2489
pubmed: 32051492
J Immunol Res. 2020 Sep 19;2020:2549763
pubmed: 33015196
Asian Pac J Cancer Prev. 2011;12(5):1141-7
pubmed: 21875256
Mol Cancer. 2018 Nov 17;17(1):158
pubmed: 30447690
EBioMedicine. 2022 Dec;86:104357
pubmed: 36371985
Appl Bionics Biomech. 2022 Jan 27;2022:8537966
pubmed: 35126664
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898
pubmed: 32634781
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):E3473-82
pubmed: 23161911
Head Neck Pathol. 2013 Mar;7(1):73-5
pubmed: 23015393
J Natl Cancer Inst. 2011 Dec 7;103(23):1761-70
pubmed: 22056739
Ann Nasopharynx Cancer. 2022 Jun;6:
pubmed: 35996401
J Can Dent Assoc. 2016 Jan;82:g2
pubmed: 27548665
Cancer. 2013 May 15;119(10):1838-44
pubmed: 23436393
Virol J. 2005 Apr 20;2:39
pubmed: 15842731

Auteurs

Naveed Ahmed (N)

Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.

Mai Abdel Haleem A Abusalah (MAHA)

Faculty of Medical Allied Science, Zarqa University, Zarqa 13110, Jordan.

Anam Farzand (A)

Department of Allied Health Science, Superior University, Lahore 54000, Pakistan.

Muhammad Absar (M)

Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.

Nik Yusnoraini Yusof (NY)

Institute for Research in Molecular Medicine (INFORMM), Health Campus, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.

Ali A Rabaan (AA)

Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.
College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Department of Public Health and Nutrition, The University of Haripur, Haripur 22610, Pakistan.

Hajir AlSaihati (H)

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin 39831, Saudi Arabia.

Amer Alshengeti (A)

Department of Pediatrics, College of Medicine, Taibah University, Al-Madinah 41491, Saudi Arabia.
Department of Infection Prevention and Control, Prince Mohammad Bin Abdulaziz Hospital, National Guard Health Affairs, Al-Madinah 41491, Saudi Arabia.

Sara Alwarthan (S)

Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.

Haifa S Alsuwailem (HS)

Department of Medicine, College of Medicine, Princess Norah Bint Abdulrahman University, Riyadh 84428, Saudi Arabia.

Zainb A Alrumaih (ZA)

College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.

Ahmed Alsayyah (A)

Department of Pathology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.

Chan Yean Yean (CY)

Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.
Institute for Research in Molecular Medicine (INFORMM), Health Campus, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH